# Normal fetal neurodevelopment; healthy control population as a comparison for fetuses with a congenital heart disease

No registrations found.

**Ethical review** Positive opinion

**Status** Recruiting

**Health condition type** - **Study type** - Observational non invasive

## **Summary**

#### ID

NL-OMON26893

**Source** 

Nationaal Trial Register

**Brief title** FEND study

**Health condition** 

Congenital heart disease Intra-uterine neurodevelopmental disorders

## **Sponsors and support**

**Primary sponsor:** Leiden University Medical Center

Source(s) of monetary or material Support: No funding

## Intervention

#### **Outcome measures**

#### **Primary outcome**

- 1. Brain age of healthy control fetuses, especially in the third trimester (cortical folding of the brain)
  - 1 Normal fetal neurodevelopment; healthy control population as a comparison for fe ... 14-05-2025

2. Speed of maturation of healthy control fetuses, especially in the third trimester

## **Secondary outcome**

- 1. Brain perfusion of healthy control fetuses
- 2. Growth trajectories of brain structures
- 3. Brain volume of healthy control fetuses
- 4. Collection of placentas and biomaterial of the umbilical cords for storage for future research. The biomaterials will be stored in the LUMC Biobank Verloskunde

## **Study description**

## **Background summary**

Rationale: Congenital heart disease (CHD) is the most prevalent congenital anomaly and accounts for significant (neonatal) mortality and morbidity. Not only cardiovascular and surgical problems can arise, also a high percentage of CHD children suffer from neurodevelopmental disorders. Recent imaging studies found signs of abnormal neurological development already present at birth. However, the precise intrauterine pathophysiology is not known. The current study is designed to analyse the normal fetal neurodevelopment and to collect biomaterial of healthy fetuses for the LUMC Biobank Verloskunde, to serve as a control group for fetuses with congenital heart defects. In the department of fetal medicine of the LUMC, all consecutive CHD fetuses are systematically included in a fetal neurodevelopmental surveillance program (Heart And Neurodevelopmental Program). Data and biomaterial of fetuses with CHD are stored in the LUMC Biobank Verloskunde.

Objective: To study prenatal normal intrauterine cerebral developmental as a comparison for neurodevelopment in fetuses with CHD, to identify possible prognostic factors for abnormal neurodevelopmental outcome in children

with CHD. To collect and store placentas and biomaterial of the umbilical cord of healthy control fetuses in our LUMC Biobank congenital heart disease for future research.

Study design: Single-center, prospective, observational cohort study

Study population: Pregnant women carrying a congenitally normal fetus

Main study parameters/endpoints: brain age, intrauterine development of the brain, speed of maturation

Secondary study parameters/endpoints: brain perfusion, growth trajectories of brain structures, brain volumes, collection of placentas and biomaterial of the umbilical cord for storage in the LUMC Biobank Verloskunde.

#### Study objective

2 - Normal fetal neurodevelopment; healthy control population as a comparison for fe ... 14-05-2025

Fetuses with a congenital heart disease show a delay in cortical maturation especially in the third trimester, in comparison with healthy control cases.

## Study design

20-24-28-32 and 36 weeks of gestational age Birth

## **Contacts**

#### **Public**

Leiden University Medical Center Albinusdreef 2, 2333 ZA Leiden The Netherlands Moska Aliasi

+31(0)71 5269199

#### **Scientific**

Leiden University Medical Center Albinusdreef 2, 2333 ZA Leiden The Netherlands Moska Aliasi

+31(0)71 5269199

# **Eligibility criteria**

#### Inclusion criteria

- Singleton pregnancy
- Normal second trimester ultrasound (absence of abnormalities on ultrasound)
- No use of alcohol, drugs or other psychoactive substances during pregnancy
- Age ≥ 18 years
- Gestational age 18-36 weeks

## **Exclusion criteria**

- Obstetric history of intra-uterine growth restriction or intra-uterine fetal demise
- Serious underlying maternal medical condition
- Use of teratogenic medication during pregnancy
- Congenital abnormalities detected in the first year of life

# Study design

## **Design**

Study type: Observational non invasive

Intervention model: Other

Allocation: Non controlled trial

Masking: Open (masking not used)

Control: Active

## Recruitment

NL

Recruitment status: Recruiting
Start date (anticipated): 01-10-2020

Enrollment: 70

Type: Anticipated

## **IPD** sharing statement

Plan to share IPD: No

## **Ethics review**

Positive opinion

Date: 04-11-2020

Application type: First submission

# **Study registrations**

# Followed up by the following (possibly more current) registration

ID: 49553

Bron: ToetsingOnline

Titel:

## Other (possibly less up-to-date) registrations in this register

No registrations found.

# In other registers

Register ID

NTR-new NL9035

CCMO NL72889.058.20 OMON NL-OMON49553

# **Study results**